WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4804
[post_author] => 4
[post_date] => 2025-03-20 12:10:54
[post_date_gmt] => 2025-03-20 16:10:54
[post_content] =>
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
Application Deadline: May 15, 2025, 5pm ET
Learn more about the program, get information session details and access the full request for proposals here: https://centerforbiotechnology.org/what-we-do/technology-development/reach/
[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards
[post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.)
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => news-reach25
[to_ping] =>
[pinged] =>
[post_modified] => 2025-03-24 12:11:36
[post_modified_gmt] => 2025-03-24 16:11:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4804
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3083
[post_author] => 3
[post_date] => 2018-11-16 14:26:57
[post_date_gmt] => 2018-11-16 14:26:57
[post_content] => Update courtesy of BBC Entrepreneurial Training and Consulting
NIH is strongly encouraging small businesses to contact the appropriate Institute or Center early in their application planning to ensure their technology is a priority for the Institute/Center.
An updated SBIR/STTR Application Guide with additional instructions for SBIR Direct Phase II application preparation and submission will be posted by November 26, 2018. The following sections of each FOA are changed:
Part 2, Section I. Funding Opportunity Description The following has been added at the end of the section for each FOA:
PA-18-573 The following Components will not accept an SBIR Direct-to-Phase II submission:
- National Institute of Nursing Research (NINR)
- National Center for Complementary and Integrative Health (NCCIH)
PA-18-574 The following Components will not accept an SBIR Direct-to-Phase II submission:
- National Institute of Environmental Health Sciences (NIEHS )
- National Institute of Nursing Research (NINR)
- National Center for Complementary and Integrative Health (NCCIH)
- Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)
- Centers for Disease Control and Prevention (CDC) (All Components of CDC)
- U.S. Food and Drug Administration (FDA) (All Components of FDA)
Part 2, Section II. Award Information for both PA-18-573 and PA-18-574. Application types now allowed are:
- New (Phase I, Fast-Track)
- New (Direct Phase II)
- Renewal (Phase II)
- Resubmission (all phases)
- Phase IIB Competing Renewal (Phase IIB)
- Revision
The OER Glossary and the SF424 (R&R) SBIR/STTR Application Guide provide details on these application types.
[post_title] => Important SBIR/STTR Information Update from NIH
[post_excerpt] => An updated SBIR/STTR Application Guide with additional instructions for SBIR Direct Phase II application preparation and submission will be posted by November 26, 2018.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => important-sbirsttr-information-update-from-nih
[to_ping] =>
[pinged] =>
[post_modified] => 2018-11-16 14:26:57
[post_modified_gmt] => 2018-11-16 14:26:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=3083
[menu_order] => 110
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 1423
[post_author] => 3
[post_date] => 2015-02-25 22:55:49
[post_date_gmt] => 2015-02-25 22:55:49
[post_content] => Springboard's Health Innovation Hub is a collaboration platform advancing the growth of women-led digital health and life science companies with access to sources of funding, partnerships, and advisors. Learn more on their website, download the 1-pager, or apply here.
[post_title] => Springboard Enterprises' Health Innovation Hub
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => springboard-enterprises-health-innovation-hub
[to_ping] =>
[pinged] =>
http://sb.co/hih15/
[post_modified] => 2016-03-02 18:00:26
[post_modified_gmt] => 2016-03-02 18:00:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1423
[menu_order] => 213
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 3892
[post_author] => 4
[post_date] => 2022-06-16 17:26:49
[post_date_gmt] => 2022-06-16 17:26:49
[post_content] =>
The Center for Biotechnology on behalf of the Long Island Bioscience Hub is pleased to announce a request for proposals for our two-tiered technology development & commercialization program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
Faculty and postdoctoral associates, alone or in partnership with companies or CFB-appointed BioEntrepreneurs-in-Residence (BEIRs), are eligible to apply. In all instances, the faculty member or post-doctoral associate must serve as the principal investigator, and the project must be executed on the academic campus at Stony Brook University.
Application Deadline: Monday, July 18, 2022, 5pm ET
Interested applicants are strongly recommended to connect with the Center for Biotechnology team before writing a full proposal and submission. Please contact William Hanes, JD, PhD, at the Center for Biotechnology: William Hanes, JD, PhD, william.hanes@stonybrook.edu.
Program was made possible with the generous support of the NIH-REACH program, NYSTAR, Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, Feinstein Institute for Medical Research, SUNY Research Foundation, and Empire State Development
[post_title] => Funding Opportunity: Development and Commercialization of Bio-Based Technologies for Human Health and National Health Security
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => reach0622
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 17:05:05
[post_modified_gmt] => 2022-12-13 17:05:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3892
[menu_order] => 25
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 5
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4804
[post_author] => 4
[post_date] => 2025-03-20 12:10:54
[post_date_gmt] => 2025-03-20 16:10:54
[post_content] =>
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
Application Deadline: May 15, 2025, 5pm ET
Learn more about the program, get information session details and access the full request for proposals here: https://centerforbiotechnology.org/what-we-do/technology-development/reach/
[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards
[post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.)
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => news-reach25
[to_ping] =>
[pinged] =>
[post_modified] => 2025-03-24 12:11:36
[post_modified_gmt] => 2025-03-24 16:11:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4804
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 265
[max_num_pages] => 89
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)